HA35 Moderate Alcoholic Hepatitis (AH) Study

Alcoholic Hepatitis Clinical Trial

Official title:

Mechanism of HA35 in Patients With Alcoholic Liver Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05018481
• Other study ID #: 21-605
• Status: Recruiting
• Phase: Early Phase 1
• Start date: September 1, 2022
• Est. completion date: October 1, 2025

Study information

• Verified date: July 2023
• Source: The Cleveland Clinic
• Contact: Srinivasan Dasarathy, MD
• Phone: 216-318-7010
• Email: dasaras[@]ccf.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Eligible participants will be asked to take a placebo/treatment capsule for 90 days and participate in two in-person study visits, one at the start of the 90 days and the second at the completion of study supplement administration. Both visits will include a physical exam, clinical labs, body composition measurements, muscle strength tests, questionnaires, and urine and stool collections. Additionally, a sugar cocktail will be consumed to measure gut permeability and a muscle biopsy will be collected. The day after the visits, you will need to return to drop off the 24-hour urine collection. Two phone visits will be performed in between the in-person visits at day 30 and 60 where you will be asked a series of questionnaires as well as asked about study supplement compliance.

Description:

Written informed consent will be obtained during the baseline visit (day 1). Patients will given a physical exam and a blood test will be obtained if not in their medical chart. The subjects who meet the criteria after the screening visit will have the following procedures: A. Body composition will be quantified by whole-body dual energy X-ray absorptiometry (DEXA), Bioelectric Impedance Analysis (BIA), chair stands, 3 position balance and hand grip strength by dynamometry. B. Muscle biopsy from the lateral portion of vastus lateralis, about 20 cm above knee, C. Questionnaires, D. Blood collection, E. Collection of stool samples, F. Sugar cocktail administration, and G. Urine collection (24 hour) After baseline measures have been completed, patients will be randomized in a 1:1 ratio to either standard of care (SOC) + HA35 or SOC + placebo (140 mg/d) for a total of 3 months post enrollment. The subjects will be recalled after 3 months. The visit and the procedures conducted on day 90 will be similar to the baseline study visit.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: October 1, 2025
• Est. primary completion date: October 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of alcoholic hepatitis defined as:
• Regular consumption of alcohol with an intake of >60 g daily or >420 g weekly on average for men and >40 g daily or >280 g weekly on average for women for 6 months or more AND
• MELD <21
• Serum total bilirubin >3 mg/dL
• AST >50 IU/I; AST:ALT ratio >1.5; Both AST and ALT <400 IU/I OR Histologic evidence of AH.

Exclusion Criteria:

• Pregnant or breastfeeding women
• Patients with gastrointestinal bleeding within 2 weeks
• Active infection (positive blood or ascitic fluid culture)
• Overt encephalopathy
• Renal failure and/or on dialysis
• Medications that alter muscle protein metabolism
• Myopathies
• Other end-stage organ diseases
• Malignancy
• Solid organ or hematopoietic transplantation
• Active alcohol withdrawal or ongoing participation in a Clinical Institute Withdrawal Assessment (CIWA) protocol
• History of recent upper gastrointestinal resection within past 6 months
• Acute or chronic liver disease due to other active causes, in addition to alcoholic liver disease
• Inability to provide consent
• Creatinine >2mg/dL
• Platelets <60,000k/ul
• PT/INR >1.7
• Presence of pedal edema
• Use of anti-platelet/anticoagulation drugs or medications that interfere with blood clotting

Related Conditions & MeSH terms

• Alcoholic Hepatitis
• Hepatitis
• Hepatitis A
• Hepatitis, Alcoholic

Intervention

Drug:
• Sodium Hyaluronate
Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants
• Placebo
A placebo will be given in capsule form to study participants

Locations

Country	Name	City	State
United States	Cleveland Clinic	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare percent change of skeletal muscle mass		Baseline to 90 days